Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Chinook Therapeutics Inc (NQ: KDNY )

24.19 -0.06 (-0.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Chinook Therapeutics Inc

< Previous 1 2 Next >
Bragar Eagel & Squire, P.C. Is Investigating Integra, and Chinook and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
CHINOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Chinook Therapeutics, Inc. on Behalf of Chinook Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Chinook Therapeutics, Inc. (KDNY) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Where Chinook Therapeutics Stands With Analysts
 
Via Benzinga
Recap: Chinook Therapeutics Q1 Earnings
 
Via Benzinga
Chinook Therapeutics Trial Pause: Unfortunate But Analyst Reassures No Damage To Value Drivers
 
Via Benzinga
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Chinook Therapeutics, Inc. (KDNY) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Chinook Therapeutics, Inc. (KDNY) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Chinook Therapeutics Earnings Perspective: Return On Capital Employed
 
Via Benzinga
Where Chinook Therapeutics Stands With Analysts
 
Via Benzinga
Chinook Therapeutics's Return On Capital Employed Insights
 
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
KDNY INVESTOR NEWS: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Chinook Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – KDNY
From The Rosen Law Firm, P.A.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023
 
Via Benzinga
Analyst Views Multiple Opportunities For Chinook To Thrive In Emerging Renal Markets, Sees More Than 100% Upside
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
 
Via Benzinga
Why Vera Stock Crashed 60% On Its 'Positive' Kidney Drug Update — And Chinook Popped
The "devil is in the details" when it comes to comparing data across studies. 
Via Investor's Business Daily
20 Favorite Biotech & Medical Stocks For 2023
The way these stocks are setting up, many of them look great and will be at the forefront this coming year. 
Via Talk Markets
Have A Look At William Blair's Top Biotech Picks For 2023
William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022
 
Via Benzinga
7 Cheap Biotech Stocks to Buy Now
These cheap biotech stocks to buy offer investors a way to get ready for the inevitable comeback in the biopharmaceutical sector. 
Via InvestorPlace
Chinook Secures Orphan Drug Status From European Commission For Kidney Disease Drug
Chinook Therapeutics, Inc. (NASDAQ: KDNY) announced that the European Commission has granted orphan drug designation for BION-1301 for the treatment of primary IgA nephropathy (IgAN). 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Daily Biotech Pulse: Third FDA Rejection For Verrica's Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva's Chikungunya Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2022
Upgrades 
Via Benzinga
21 Stocks Moving in Wednesday's Pre-Market Session
Gainers The Singing Machine Company, Inc. (NASDAQ: MICS) shares rose 47.3% to $4.05 in pre-market trading. 
Via Benzinga
88 Biggest Movers From Yesterday
Gainers The Very Good Food Company Inc. (NASDAQ: VGFC) shares jumped 118.2% to close at $0.2950 on Wednesday as the company announced it increased retail distribution across Canada with Loblaw... 
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers The Very Good Food Company Inc. (NASDAQ: VGFC) gained 178.3% to $0.3762 as the company announced it increased retail distribution across Canada with Loblaw Companies. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.